Zetagen Therapeutics, a biopharmaceutical firm specializing in advanced treatments for metastatic cancers, has successfully secured a substantial $9.79 million in its Series B funding round. The company is renowned for its relentless pursuit of innovations targeting cancers affecting bones and soft tissue organs as well as osteologic interventions.

CEO Joe C. Loy expressed his optimism, highlighting that the funds will fast-track the company’s diverse array of oncologic treatments. Each asset in its portfolio is set to benefit, and Zetagen Therapeutics aims to expand its expertise to ensure the successful rollout of these critical therapies.

Zetagen Therapeutics isn’t new to industry recognition. The US Food and Drug Administration (FDA) has previously honored the company with two Breakthrough Device Designations for their treatments, ZetaMet and ZetaFuse. Additionally, they have secured multiple patents from the U.S. Patent and Trademark Office (USPTO). Its funding reservoir includes Series A and B rounds, grants from the National Institute of Health (NIH) / National Cancer Institute (NCI), and investments from angel investors.

The newly acquired funds will primarily support ZetaMet, Zetagen Therapeutics’ flagship treatment currently undergoing Phase 2a clinical trials targeting metastatic breast cancer bone lesions. The funding will also advance ZetaMAST, a treatment for metastatic lesions in soft tissue organs, and bolster other pipeline assets. As these projects move forward, Zetagen Therapeutics plans to onboard new talent to contribute to their success.

Nikhil Thakur, MD, and Co-founder of Zetagen Therapeutics, emphasized the company’s dedication to potentially life-altering research. He expressed confidence in the potential of ZetaMet, ZetaMAST, and other clinical programs to revolutionize late-stage cancer treatments.

Key financiers in this round included New York Ventures, Consolidated Capital Investments, LLC, and a collective of private investors.

Established in 2015, Zetagen Therapeutics has been at the forefront of metastatic cancer treatments. After obtaining exclusive licensing rights from the State University of New York in 2016, the company has made significant strides. Their solutions, ZetaMet and ZetaMAST, promise novel pathways for patients, potentially setting new treatment standards for those with metastatic lesions.

  Consolidated Capital Investments, Joe C. Loy, New York Ventures, Nikhil Thakur, USA, ZetaFuse, Zetagen Therapeutics, ZetaMet